Company intelligence / Profile preview
Synairgen
Southampton, England, United Kingdomnihr.ac.uk ↗
- Ownership
- Private
- Employees
- ~36
- Development stage
- Phase 3
01
Overview
Synairgen’s lead asset SNG001—an inhaled interferon beta—is being developed as a broad-spectrum antiviral therapy targeting severe respiratory viral infections. Early trials showed promise in reducing risk of severe COVID‑19; however, larger studies such as the SPRINTER Phase III trial did not meet primary endpoints but suggested potential benefit in certain subgroups. The next clinical focus will be on critically ill patients requiring mechanical ventilation due to respiratory viruses.[2][4]
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Inhaled biologics (interferon beta)Protein therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
US National Institutes of Health/NIAID ACTIV program partnership for independent evaluation of SNG001 in outpatient settings during the pandemic.[4]
Beyond the preview
Go deeper on Synairgen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synairgen.